RPbio Inc.

RPbio Inc.

KKRX:314140
4,990.00
KRW
-110.00
(-2.16%)
777.91EPS
6.80P/E
45.76BMarket Cap

Total Valuation

KRW

As of June 30, 2026, RPbio Inc. carries a market capitalization of 45.76B, placing it among publicly traded companies globally. Its enterprise value stands at 45.24B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap45.76B
Enterprise Value45.24B

Share Statistics

As of June 30, 2026, RPbio Inc. has 8.65M shares outstanding.

Shares Outstanding8.65M

Valuation Ratios

As of June 30, 2026, RPbio Inc. trades at a trailing price-to-earnings ratio of 6.80. The price-to-sales ratio is 0.32, and the price-to-book ratio stands at 0.39.

PE Ratio6.80
PS Ratio0.32
PB Ratio0.39
P/TBV Ratio0.39
P/FCF Ratio5.93
P/OCF Ratio3.84

Enterprise Valuation

As of June 30, 2026, RPbio Inc. trades at an EV/EBITDA multiple of 3.34 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.32 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 6.05 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. RPbio Inc. trades at an EV/FCF ratio of 5.47, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 45.24B versus a market cap of 45.76B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales0.32
EV / EBITDA3.34
EV / EBIT6.05
EV / FCF5.47

Financial Position

As of June 30, 2026, RPbio Inc. maintains a current ratio of 1.42, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 16.48, indicating elevated leverage, while an interest coverage ratio of 22.62 demonstrates strong ability to service its debt obligations.

Current Ratio1.42
Quick Ratio0.40
Debt / Equity16.48
Debt / EBITDA1.42
Interest Coverage22.62

Financial Efficiency

KRW

Over the twelve months ended June 30, 2026, RPbio Inc. posted a return on equity (ROE) of 6.07, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 5.26 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 4.10, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 5.56, useful for judging operating efficiency across full business cycles. The company generates approximately 270.02M in revenue per employee across its workforce of 523.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.44 indicates how many times RPbio Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)6.07
Return on Assets (ROA)4.10
Return on Invested Capital (ROIC)5.26
Return on Capital Employed (ROCE)5.56
Revenue Per Employee270.02M
Employee Count523.75
Inventory Turnover4.44

Taxes

KRW

Over the twelve months ended June 30, 2026, RPbio Inc. recorded 496.65M in income tax expense. That works out to an effective tax rate of 6.88, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 7.22B, leaving 6.73B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax496.65M
Effective Tax Rate6.88

Stock Price Statistics

KRW

As of the close on November 17, 2026, RPbio Inc.'s stock has declined approximately 36.76% over the past 52 weeks. The 50-day moving average sits at 5,609.40, while the 200-day moving average is 5,968.95.

52-Week Price Change-36.76%
50-Day Moving Average5,609.40
200-Day Moving Average5,968.95

Income Statement

KRW

Over the twelve months ended June 30, 2026, RPbio Inc. generated 141.42B in revenue and converted that into 6.73B in net income, yielding earnings per share of 777.91. EBITDA reached 13.55B, while operating income came in at 7.47B.

Revenue141.42B
Gross Profit16.45B
Operating Income7.47B
Pretax Income7.22B
Net Income6.73B
EBITDA13.55B
EBIT7.47B
Earnings Per Share (EPS)777.91

Balance Sheet

KRW

As of June 30, 2026, RPbio Inc. holds 19.76B in cash and equivalents against 19.24B in total debt, resulting in a net debt position of 5.72B. Total book value stands at 116.75B, with working capital of 20.59B providing operational flexibility.

Cash & Cash Equivalents19.76B
Total Debt19.24B
Net Debt5.72B
Equity (Book Value)116.75B
Book Value Per Share13,497.24
Working Capital20.59B

Cash Flow

KRW

RPbio Inc. produced 11.91B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -4.20B in capital expenditures, free cash flow totaled 7.71B - equivalent to 891.86 per share.

Operating Cash Flow11.91B
Capital Expenditures-4.20B
Free Cash Flow7.71B
FCF Per Share891.86

Margins

Over the twelve months ended June 30, 2026, RPbio Inc. posted a gross margin of 11.64, reflecting its pricing power and cost economics. The operating margin of 5.28 and net profit margin of 4.76 provide insight into operational efficiency.

Gross Margin11.64
Operating Margin5.28
Pretax Margin5.11
Profit Margin4.76
EBITDA Margin9.58

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 16.86, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 1.18, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to RPbio Inc. shareholders.

Shareholder Yield1.18
FCF Yield16.86

Scores

As of June 30, 2026, RPbio Inc. has an Altman Z-Score of 2.02, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.02